{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-027354","form_type":"8-K","ticker":"MANE","cik":"0001827635","company_name":"Veradermics, Inc","filed_at":"2026-04-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.031502+00:00","generated_at":"2026-05-15T03:57:38.278446+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"Veradermics' VDPHL01 meets all primary and key secondary endpoints in Phase 2/3 male hair loss trial","bullets":["VDPHL01 achieved mean TAHC increase of 30.3 hairs/cm² (QD) and 33.0 hairs/cm² (BID) vs 7.3 for placebo at Month 6 (p<0.0001)","79.3% (QD) and 86.0% (BID) of patients reported improvement on AAIRS vs 35.6% placebo","No treatment-related serious adverse events or cardiac adverse events of special interest observed","Statistically significant separation from placebo observed as early as Month 2"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-027354","json":"https://secwatch.observer/filing/0001628280-26-027354.json","markdown":"https://secwatch.observer/filing/0001628280-26-027354.md","text":"https://secwatch.observer/filing/0001628280-26-027354.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1827635/000162828026027354/0001628280-26-027354-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1827635/000162828026027354/mane-20260427.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-15T03:57:38.278446+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}